For adults only. Patients with hypercholesterolemia (type Ha) or with pure (type IV) or combined (types fib and Ill) endogenous hypertrigliceridemia. - when appropriate caloric restriction alone has been unsuccessful in achieving desired lipid reduction. - more particularly when cholesterol levels are still high following dietary treatment and/or with existing associated risk factors. Dietary control should be continued as an adjunct to drug treatment. No long-term controlled trials are available to establish whether or not fe-nofibrate has a beneficial effect in the primary or secondary prevention of atherosclerosis related complications. Contra-Indications: - Severe renal or hepatic dysfunction, - Children. Precautions: - Concurrent use of other drugs (anticoagulants) - Pregnancy - Lactation. Should be notified_tathe playsician_bafora starting traatmant_ EFFECTS ON ACTIVITIES REQUIRING ALERTNESS SUCH AS DRIVING A MOTOR VEHICLE OR OPERATING HEAVY MACHINERY OR AP-PLIANCES.
No case of drowsiness has been reported.
Adverse reactions Seldom seen and mild: - Digestive symptoms (gastric or intestinal upset ) - Skin allergic reactions - Transient elevation of transaminases. Dosage and administration : As physician directs. One 300 mg capsule daily with one of the principal meals as an adjunct to dietary measures. Availability : Capsules in blister pack cartons of 30.
/W NAP HARM Under Licence of FOURNIER - FRANCE
Fl
MINAPHAPM
ليست هناك تعليقات:
إرسال تعليق